Rain Therapeutics to Present at Citi’s 15th Annual BioPharma Virtual Conference


NEWARK, Calif., September 3, 2020 — Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, today announced that Avanish Vellanki, chairman and chief executive officer of Rain, will present a corporate overview at Citi’s 15th Annual BioPharma Virtual Conference being held September 8-10, 2020.

Citi’s Annual BioPharma Conference
Date: Tuesday, September 8
Time: 10:05 a.m. EDT

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing targeted therapies for patients with cancer. Rain’s lead program is RAIN-32, a small molecule MDM2 inhibitor for patients with well-differentiated and de-differentiated liposarcoma, and other indications exhibiting MDM2 gene amplification or overexpression. RAIN-32 has completed clinical trials in certain solid tumors and hematological malignancies.  Tarloxotinib, a hypoxia-activated pan-HER inhibitor is in clinical trials for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations and HER2 activating mutations, as well as a tumor-agnostic cohort for patients with NRG1, EGFR, HER2, and HER4 fusions. Rain is also developing a potential first-in-class inhibitor of RAD52 in the DNA Damage Response (DDR) pathway as a synthetic lethal strategy for tumors with BRCA1/2 mutations.   For more information, visit www.rainthera.com.

Media Contact for Rain

Cait Williamson, PhD
LifeSci Communications